N,N-dimethyl-3-((5-nitropyridin-2-yl)oxy)-3-phenylpropan-1-amine | 1584114-22-6

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: N,N-dimethyl-3-((5-nitropyridin-2-yl)oxy)-3-phenylpropan-1-amine
• CAS: 1584114-22-6
• 化学式: C₁₆H₁₉N₃O₃
• 分子量: 301.345
• InChiKey: LLLSRQSWEXSDBV-UHFFFAOYSA-N

物化性质

• 沸点：
  448.2±45.0 °C(predicted)
• 密度：
  1.189±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.06
• 重原子数：
  22.0
• 可旋转键数：
  7.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  68.5
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-3-((5-nitropyridin-2-yl)oxy)-3-phenylpropan-1-amine 在 platinum(IV) oxide 、 叠氮磷酸二苯酯 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 6.0h， 生成 1-[6-[3-(Dimethylamino)-1-phenylpropoxy]pyridin-3-yl]-3-(1-methylindol-5-yl)urea
  参考文献：
  名称：

  Design of novel multiple-acting ligands towards SERT and 5-HT2C receptors

  摘要：

  This Letter describes our attempts to elaborate dually acting compounds possessing serotonin re-uptake transporter inhibitor and serotonin 5-HT2C receptor antagonist properties. A novel series of 1,3-diphenylureas and N-phenylbenzamides have thus been prepared and evaluated. Based on its in vitro and in vivo activities, as well as pharmacokinetic profile, compound 16a was identified as a lead compound. The synthesis and structure-activity relationship of this series of compounds is presented herein. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.043
• 作为产物：
  描述：

  3-二甲基氨基-1-苯丙烷-1-酮 在 sodium tetrahydroborate 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 48.0h， 生成 N,N-dimethyl-3-((5-nitropyridin-2-yl)oxy)-3-phenylpropan-1-amine
  参考文献：
  名称：

  Design of novel multiple-acting ligands towards SERT and 5-HT2C receptors

  摘要：

  This Letter describes our attempts to elaborate dually acting compounds possessing serotonin re-uptake transporter inhibitor and serotonin 5-HT2C receptor antagonist properties. A novel series of 1,3-diphenylureas and N-phenylbenzamides have thus been prepared and evaluated. Based on its in vitro and in vivo activities, as well as pharmacokinetic profile, compound 16a was identified as a lead compound. The synthesis and structure-activity relationship of this series of compounds is presented herein. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.043